Stocktoria
Avalo Therapeutics, Inc. AVTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-11-13
Avalo Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $59,000 | $441,000 | $1.9M | $18.1M | $5.4M |
| SG&A expense | — | — | $10.3M | $20.7M | — |
| Operating income | -$72.9M | -$68.5M | -$27.4M | -$37.4M | -$82.1M |
| Income tax | $165,000 | $114,000 | $14,000 | $28,000 | -$196,000 |
| Net income | -$78.3M | -$35.1M | -$31.5M | -$41.7M | -$84.4M |
| EPS (diluted) | $-5.84 | $-20.91 | $-113.58 | $-1063.00 | — |
| Operating cash flow | -$51.5M | -$49.1M | -$30.7M | -$26.8M | -$70.9M |
| Free cash flow | — | — | — | -$26.8M | -$71.0M |
| Cash & equivalents | $15.9M | $134.5M | $7.4M | $13.2M | $54.6M |
| Inventory | — | — | $0 | $20,000 | $38,000 |
| Total assets | $116.5M | $150.7M | $21.0M | $33.4M | $80.2M |
| Total liabilities | $33.4M | $17.7M | $13.7M | $44.3M | $57.1M |
| Shareholders' equity | $83.0M | $133.0M | $7.3M | -$10.9M | $23.1M |
Source: SEC EDGAR filings · CIK 0001534120 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.